Darcy Lewis

Articles

Guidelines Address Questions About Evaluating Less Common HER2 Testing Patterns

December 12th 2019

For the past 2 decades, clinical guidelines for the diagnosis and management of breast cancer have sought to clarify the definition of HER2 status, but several key questions remain.

Immunotherapy for Breast Cancer: What's New and What's on the Horizon?

October 7th 2019

Immunotherapy may finally be taking center stage in breast cancer, although much work remains to be done.

Earlier Diagnosis and Treatment Are Next Steps in TNBC Paradigm

October 7th 2019

There is an unprecedented array of therapeutic options for patients with triple-negative breast cancer, with more approaches on the horizon.

Use of Neoadjuvant Endocrine Therapy Showcases Testing Capabilities in Breast Cancer

October 6th 2019

In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.

Trends in Pathologic Complete Response After Neoadjuvant Chemo in Breast Cancer

October 5th 2019

In contemporary breast cancer clinical practice, the correlation between achieving a pathologic complete response after neoadjuvant chemotherapy and significantly improved outcomes after chemotherapy has been well established. However, in a discussion at the 2019 Lynn Sage Breast Cancer Symposium, William J. Gradishar, MD, cautioned colleagues that there is more to the story when one looks at long-term data in these patients.

Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer

October 5th 2019

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

Updated HER2+ Breast Cancer Guidelines Offer Additional Insight, But Questions Remain

October 4th 2019

Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.

What's Keeping CAR T-Cell Therapies From the Outpatient Setting?

March 13th 2019

Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending chimeric antigen receptor T-cell therapies to the outpatient setting.

Ibrutinib/Palbociclib Combo Shows Activity in Previously Treated MCL

February 21st 2019

Combining ibrutinib with the CDK4/6 inhibitor palbociclib appeared to be well tolerated and active in patients with previously treated mantle cell lymphoma.

Opioid Crisis Spurs New Strategies for Cancer Pain

January 17th 2019

Major cancer centers are examining their current protocols to develop new ways to manage pain with shorter courses of opioids—or, if appropriate, with nonopioid approaches.

Molecular Profiling in Metastatic Breast Cancer: Not Yet Standard of Care, But May Be in Near Future

October 14th 2018

As the cost of sequencing continues to fall, genomic testing will likely become widespread in all types of metastatic cancer, including breast cancer.

Predictive Value Examined Among Genomic Tests for Breast Cancer

October 14th 2018

Multiple gene signature assays have been developed that supply prognostic information for decisions on adjuvant chemotherapy and whether therapy should be of extended duration.

Progress Emerging With Optimal Adjuvant Therapy in Young Women With Breast Cancer

October 14th 2018

Determining the optimal adjuvant therapy in young women with breast cancer remains challenging, but some clarity is beginning to emerge.

Conventional View May Not Apply for All Triple-Negative Breast Cancers

October 13th 2018

All triple-negative breast cancers are not created equal, and clinicians should consider their inherent heterogeneity during diagnosis and treatment planning.

Emerging Role of TILs in Breast Cancer Leads to Expanding Pathology Practices

October 12th 2018

Just as immunotherapies are transforming clinical practice for oncologists, these new therapies are also changing the practice of pathology and offering new ways for oncologists and pathologists to collaborate and improve patient care.

Expanded FDA Clearances Speed Scalp Cooling Acceptance in Oncology Community

October 12th 2018

Scalp cooling to limit alopecia in patients with cancer who are receiving chemotherapy is edging closer to becoming a widespread patient offering following recent FDA clearances.

Longer Survivals Move Cardiotoxicity Issues to Forefront

September 26th 2018

The discipline of cardio-oncology is steadily rising as a necessary intermediary to build understanding of these adverse events and focus efforts on developing solutions.

Ibrutinib-containing Combination Induced High Rate of Bone Marrow MRD Negativity, 100% ORR in IGHV-Mutated CLL

July 12th 2017

Patients with IGHV-mutated chronic lymphocytic leukemia had high rates of minimal residual disease-negative status in bone marrow following first-line treatment with a combination of ibrutinib (Imbruvica), fludarabine, cyclophosphamide, and obinutuzumab.

Maintenance Olaparib Shows Promise in Platinum-Sensitive Serous Ovarian Cancer

June 16th 2017

The PARP inhibitor olaparib demonstrated clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer in a recent study.

Study Further Characterizes Niraparib PFS Benefit in Ovarian Cancer

June 9th 2017

Patients with ovarian cancer who had a partial response to previous platinum-based therapy had superior progression-free survival with or without germline BRCA mutations after treatment with niraparib (Zejula), according to a posthoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.